Inventory
The latest quarterly inventory is $462.50 Million with a quarter-over-quarter change of +2.19%. Inventory includes raw materials, work-in-progress, and finished goods held by a company for sale or for use in production.
PODD Inventory
Reported quarterly inventory; no daily interpolation.
Current Inventory
$462.50M
$462.50 Million
Quarter-over-Quarter Change
+2.19%
vs. $452.60M prior quarter
Historical Data
80
Quarters of data available
Quarterly Inventory History
| Period | Inventory | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $462.50M | +$9.90M | +2.19% |
| Q4 2025 | $452.60M | +$6.30M | +1.41% |
| Q3 2025 | $446.30M | $-600,000 | -0.13% |
| Q2 2025 | $446.90M | +$6.10M | +1.38% |
| Q1 2025 | $440.80M | +$10.40M | +2.42% |
| Q4 2024 | $430.40M | $-14.50M | -3.26% |
| Q3 2024 | $444.90M | +$14.00M | +3.25% |
| Q2 2024 | $430.90M | +$300,000 | +0.07% |
| Q1 2024 | $430.60M | +$28.00M | +6.95% |
| Q4 2023 | $402.60M | $-8.20M | -2.00% |
| Q3 2023 | $410.80M | $-500,000 | -0.12% |
| Q2 2023 | $411.30M | +$25.20M | +6.53% |
| Q1 2023 | $386.10M | +$39.30M | +11.33% |
| Q4 2022 | $346.80M | +$19.20M | +5.86% |
| Q3 2022 | $327.60M | +$7.20M | +2.25% |
| Q2 2022 | $320.40M | +$5.60M | +1.78% |
| Q1 2022 | $314.80M | +$11.60M | +3.83% |
| Q4 2021 | $303.20M | +$44.20M | +17.07% |
| Q3 2021 | $259.00M | +$61.20M | +30.94% |
| Q2 2021 | $197.80M | +$27.70M | +16.28% |
| Q1 2021 | $170.10M | +$15.80M | +10.24% |
| Q4 2020 | $154.30M | +$29.40M | +23.54% |
| Q3 2020 | $124.90M | +$21.20M | +20.44% |
| Q2 2020 | $103.70M | +$8.00M | +8.36% |
| Q1 2020 | $95.70M | $-5.30M | -5.25% |
| Q4 2019 | $101.00M | +$10.79M | +11.96% |
| Q3 2019 | $90.21M | +$5.10M | +5.99% |
| Q2 2019 | $85.11M | +$11.29M | +15.29% |
| Q1 2019 | $73.82M | +$2.41M | +3.37% |
| Q4 2018 | $71.41M | +$13.36M | +23.02% |
| Q3 2018 | $58.05M | +$17.24M | +42.25% |
| Q2 2018 | $40.81M | +$14.47M | +54.96% |
| Q1 2018 | $26.33M | $-7.46M | -22.07% |
| Q4 2017 | $33.79M | $-1.26M | -3.60% |
| Q3 2017 | $35.05M | +$1.10M | +3.23% |
| Q2 2017 | $33.96M | $-377,000 | -1.10% |
| Q1 2017 | $34.33M | $-1.18M | -3.33% |
| Q4 2016 | $35.51M | +$2.85M | +8.73% |
| Q3 2016 | $32.66M | +$8.18M | +33.39% |
| Q2 2016 | $24.49M | +$10.46M | +74.60% |
| Q1 2016 | $14.02M | +$2.00M | +16.63% |
| Q4 2015 | $12.02M | $-995,000 | -7.64% |
| Q3 2015 | $13.02M | $-10.42M | -44.45% |
| Q2 2015 | $23.43M | +$3.37M | +16.80% |
| Q1 2015 | $20.07M | +$6.97M | +53.18% |
| Q4 2014 | $13.10M | +$3.44M | +35.57% |
| Q3 2014 | $9.66M | +$897,000 | +10.23% |
| Q2 2014 | $8.77M | $-1.68M | -16.12% |
| Q1 2014 | $10.45M | +$985,000 | +10.41% |
| Q4 2013 | $9.46M | +$4.07M | +75.42% |
| Q3 2013 | $5.39M | $-584,000 | -9.77% |
| Q2 2013 | $5.98M | $-3.22M | -35.00% |
| Q1 2013 | $9.20M | $-5.67M | -38.12% |
| Q4 2012 | $14.87M | $-222,000 | -1.47% |
| Q3 2012 | $15.09M | $-1.34M | -8.14% |
| Q2 2012 | $16.43M | +$1.72M | +11.72% |
| Q1 2012 | $14.70M | +$2.87M | +24.20% |
| Q4 2011 | $11.84M | $-1.28M | -9.79% |
| Q3 2011 | $13.12M | $-2.83M | -17.76% |
| Q2 2011 | $15.96M | +$3.76M | +30.81% |
| Q1 2011 | $12.20M | +$769,000 | +6.73% |
| Q4 2010 | $11.43M | $-1.48M | -11.46% |
| Q3 2010 | $12.91M | +$2.68M | +26.18% |
| Q2 2010 | $10.23M | +$3.63M | +55.02% |
| Q1 2010 | $6.60M | $-3.49M | -34.56% |
| Q4 2009 | $10.09M | +$911,000 | +9.93% |
| Q3 2009 | $9.18M | $-1.23M | -11.86% |
| Q2 2009 | $10.41M | $-4.74M | -31.28% |
| Q1 2009 | $15.15M | $-1.72M | -10.21% |
| Q4 2008 | $16.87M | +$403,000 | +2.45% |
| Q3 2008 | $16.47M | +$3.13M | +23.48% |
| Q2 2008 | $13.34M | +$5.83M | +77.67% |
| Q1 2008 | $7.51M | $-484,000 | -6.06% |
| Q4 2007 | $7.99M | +$3.42M | +74.76% |
| Q3 2007 | $4.57M | +$443,000 | +10.73% |
| Q2 2007 | $4.13M | $-127,000 | -2.98% |
| Q1 2007 | $4.26M | +$866,000 | +25.55% |
| Q4 2006 | $3.39M | +$1.15M | +51.00% |
| Q3 2006 | $2.25M | +$1.38M | +159.84% |
| Q4 2005 | $864,000 | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy